Entering text into the input field will update the search result below

Crispr: Bad News For Gene Editing

Real Investments profile picture
Real Investments


  • New data concerning chromothripsis may affect the long-term outlook of companies such as Crispr Therapeutics.
  • The long-term impact on health of gene editing may not be known until around 2040.
  • Given the uncertain outlook, investors may be wise to re-evaluate their positions in companies employing DNA double strand breaks to edit the genome.

Meletios Verras/iStock via Getty Images

Author's Note, 09/19: Unfortunately, I misread the data concerning the number of patients who experienced adverse events, so any reference to side effects has been deleted.


I’m sure there are many investors in

This article was written by

Real Investments profile picture
I have been an active trader for more years than I can remember, During that time I have gained experience in investing in just about everything; commodities, stocks, options, and an occasional flutter with futures contracts. Fortunately, I have had some success, which has enabled me to retire from the 9 – 5.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.